Gene Findings Unlocking Reasons for Neuroblastoma Risk
... cancer.
Originating in the peripheral
nervous system, neuroblastoma is the most common solid ... by which BARD1 gene variants act on developing
nervous system cells to give rise to cancer during fetal ... genes that are involved in the development of the
nervous system, and the CNV they discovered changes how ...
Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
... the modulation of sodium channel activity in the
nervous system. Sodium channels play a crucial role in regulating the activity of the
nervous system to help nerve cells communicate. Sometimes ... medicines with a focus on the fields of central
nervous system and immunology disorders. Employing ....
Neuralstem's Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
... that the transplanted cells integrated into the
nervous system of the host. The rats had a genetic ... that they can become an integral part of the rat
nervous system that controls the muscles. I would expect ... readily accepted by and integrated into a human
nervous system, such as in an ALS or a spinal cord injury ...
New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
... patients taking Keppra XR experienced fewer
nervous system side effects than those taking the same ... lower rates of adverse events related to
nervous system disorders (i.e., headache, somnolence and ... medicines with a focus on the fields of central
nervous system and immunology disorders. Employing ...
Protein Shown to Play a Key Role in Normal Development of Nervous System
... plays a key role in controlling
the developing
nervous system. Research into how that protein helps ... for patients who suffer injuries to their
nervous system,
including spinal cord injury.
"This expands our basic knowledge of how the
nervous system develops in
animals and humans," said ...
Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
... on the treatment of
obesity and other central
nervous system-related disorders, today presented
data ... on
the treatment of obesity and other central
nervous system-related
disorders. The Company's lead ... act on a specific group of neurons in
the central
nervous system with the goal of achieving appetite ...
Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
... Drug Administration (FDA)
to treat other central
nervous system disorders. Orexigen has developed ... product candidates for the treatment
of central
nervous system disorders, including obesity. The ... other proprietary drugs for
use in other central
nervous system disorders. Further information about
the ...
Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease
... pipeline of product candidates in central
nervous system disorders,"
said Paul E. Freiman, ... Technologies and Buck focused on central
nervous system
conditions.
"With these resources and ... novel, first-in-class
agents for central
nervous system conditions and other serious unmet
medical ...
European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
... Fifty-three percent of patients reported central
nervous system
symptoms (including dizziness [28.1%], ... 4 weeks of therapy, the prevalence of
nervous system symptoms of at
least moderate severity ... treated with
regimens containing efavirenz.
nervous system symptoms are not predictive
of the less ...
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
... Fifty-three percent of patients reported central
nervous system
symptoms (including dizziness [28.1%], ... After 4 weeks of therapy, the prevalence of
nervous system symptoms of
at least moderate severity ... treated with
regimens containing efavirenz.
nervous system symptoms are not predictive
of the less ...
European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
... Fifty-three percent of patients reported central
nervous system
symptoms (including dizziness [28.1%], ... 4 weeks of therapy, the prevalence of
nervous system symptoms of at
least moderate severity ... treated with
regimens containing efavirenz.
nervous system symptoms are not predictive
of the less ...
Mayo Clinic Clarifies Diagnosis and Treatment for Rare, Serious Blood Vessel Disease of Brain and Spinal Cord
... leads to stroke or death. Primary central
nervous system vasculitis
(PCNSV) can best be identified ... of the Mayo Clinic Research
Primary central
nervous system vasculitis has two traits that make ... -- The annual incidence rate of primary central
nervous system
vasculitis was 2.4 cases per 1 million ...
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
... Fifty-three percent of patients reported central
nervous system
symptoms (including dizziness [28.1%], ... 4 weeks of therapy, the prevalence of
nervous system symptoms of at
least moderate severity ... treated with
regimens containing efavirenz.
nervous system symptoms are not predictive
of the less ...
Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
... projects are focused upon
peripheral and central
nervous system applications. To that end, Diamyd
seeks to ... that
NTDDS proposes a new and broad class of
nervous system disease therapies. Pain is transmitted ... the
synapse between the peripheral and central
nervous systems. This synapse
provides input from the ...
Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
... a chronic, progressive, often disabling disease that attacks the central
nervous system(ii). MS is caused by damage to myelin, the protective sheath surrounding nerve fibers in the central
nervous system, resulting in disrupted nerve impulses traveling to and from the ...
Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
... technology to identify novel pathways for the treatment of central
nervous system (CNS) diseases, announced today results from the first clinical ... novel pathways for small molecule therapeutics to treat various central
nervous system (CNS) diseases. Neurogenesis is the process by which endogenous ...
Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
... of many unique products in four core therapeutic areas: central
nervous system, inflammatory diseases, pain and oncology. A member of the Fortune ... Cephalon Europe markets more than 30 products in four areas: central
nervous system, pain, primary care and oncology.
The company's proprietary ...
Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
... 0.5% - 5% of adults worldwide. Fibromyalgia is believed to be a central
nervous system condition, resulting from neurological changes in how the brain ... and commercialization of innovative medicines with a focus on central
nervous system and immunology disorders. Employing around 10,000 people in over 40 ...
ADHD Genes Found; Known to Play Roles in Neurodevelopment
... the gene alterations we found are involved in the development of the
nervous system, they may eventually guide researchers to better targets in ... functions such as learning, behavior, synaptic transmission and
nervous system development.
"We took a systems biology approach, grouping ...
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
... of many unique products in four core therapeutic areas: central
nervous system, inflammatory diseases, pain and oncology. A member of the Fortune ... Cephalon Europe markets more than 30 products in four areas: central
nervous system, pain, primary care and oncology.
The company's proprietary ...
CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
... and commercializing innovative treatments for diseases of the central
nervous system (CNS), today announced that it has obtained the rights to develop ... and commercializing innovative treatments for diseases of the central
nervous system. CeNeRx's most advanced compound, a reversible inhibitor of ...
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
... in peripheral tissues such as liver and fat without affecting the central
nervous system, further validating Isis' anti-obesity therapeutic strategy.
... have significant therapeutic utility without the potential for central
nervous system toxicities that plague many centrally acting anti-obesity drugs," ...
New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
... B virus (HBV) infection or think you may be a carrier of HBV.
nervous system disorders (like multiple sclerosis or Guillain-Barre syndrome).
... fever that doesn't go away, bruising, bleeding or severe paleness.
nervous system disorders - numbness, weakness, tingling, changes in your vision or ...
New Therapy Enlists Immune System to Boost Cure Rate in a Childhood Cancer
... cure rates for children with neuroblastoma, a challenging cancer of the
nervous system.
John M. Maris, M.D., chief of Oncology at The Children's ... for pediatric cancers.
Neuroblastoma, a cancer of the peripheral
nervous system, usually appears as a solid tumor in the chest or abdomen. ...
One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials
... of a family of novel opioid receptor compounds with the potential to treat
nervous system disorders and addiction. The family of compounds was licensed to ... of diseases and medical conditions, including addiction, pain, and other
nervous system disorders. Alkermes screened the library of compounds from ...
Perceptive Informatics Introduces Medical Imaging Methodology to Accelerate Development Decisions About Alzheimer's Treatments
... that it has developed a robust medical imaging methodology for Central
nervous System (CNS) clinical trials involving Alzheimer's disease. The method, ... services a wide range of therapeutic areas, including oncology, central
nervous system, musculoskeletal, cardiovascular, and metabolism/endocrinology ...
Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
... of diagnostic and therapeutic agents across the BBB into the central
nervous system ("CNS"). The claims broadly encompass all neurological disorders, ... and therapeutic agents across the blood-brain barrier into the central
nervous system; that the allowed claims and patents, if issued, offer strong IP ...
Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
... of many unique products in four core therapeutic areas: central
nervous system, inflammatory diseases, pain and oncology. A member of the Fortune ... Cephalon Europe markets more than 30 products in four areas: central
nervous system, pain, primary care and oncology.
The company's proprietary ...
Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
... preclinical and Phase I studies--estrogen-agonist effects on the central
nervous system while protecting against breast and uterine tissue stimulation," ... enables RAD1901 to function as an estrogen agonist within the central
nervous system and thereby relieve hot flashes. RAD1901 was discovered by Eisai ....
Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
... of many unique products in four core therapeutic areas: central
nervous system, inflammatory diseases, pain and oncology. A member of the Fortune ... Cephalon Europe markets more than 30 products in four areas: central
nervous system, pain, primary care and oncology.
The company's proprietary ...
ICON and MedAvante Sign Alliance Agreement
... Aims To Enhance Precision and Reduce High Failure Rates in Central
nervous System Clinical Trials
DUBLIN and Hamilton, N.J., March 16 ... platform that addresses a major cause of clinical trial failure in Central
nervous System (CNS) development: variability in both clinical diagnosis of the ...
Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
... is believed to potentiate the
activity of these chemicals in the central
nervous system (brain and spinal
cord). While the mechanism of action of Cymbalta ... to increasing the activity of
serotonin and norepinephrine in the central
nervous system.
Cymbalta is approved in the United States for the acute and ...
Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
... products focused on inflammation and disorders of the central
nervous system. Omeros' most clinically advanced product candidates are derived ... pipeline of preclinical programs targeting inflammation and central
nervous system disorders. For more information on Omeros, visit the Company's Web ...
New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors
... from the interface between the endocrine (hormonal) system and the
nervous system, and includes carcinoid tumors and pancreatic NETs. Treatment ... in the cardiovascular, metabolic, cancer, organ transplantation, central
nervous system, dermatological, GI and respiratory areas. The company's mission is ...
AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
... NNR Therapeutics (TM), a new class of drugs for the treatment of central
nervous system diseases and disorders. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the
nervous system to promote therapeutic effects and limit adverse side effects. ...
Mission Pharmacal Launches CitraNatal(R) Assure Prescription Prenatal Vitamin
... shown to be instrumental in the baby's pre- and postnatal brain, eye and
nervous system development, increase the baby's gestation period, birth weight and ... and vitamin B6. Vitamin B6 contributes to a baby's developing brain and
nervous system(5) and may help some women reduce severe nausea or vomiting during ...
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
... is believed to potentiate the
activity of these chemicals in the central
nervous system (brain and spinal
cord). While the exact mechanism of action of ... to increasing the activity of
serotonin and norepinephrine in the central
nervous system.
Duloxetine is approved in the United States for the acute ...
FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
... are drugs that bind to and activate mu-opioid receptors in the central
nervous system. These drugs modify sensory and affective aspects of pain, inhibit ... is perceived. Norepinephrine reuptake inhibitors are a type of central
nervous system medication that increases the level of norepinephrine in the brain ...
Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
... 0.5% - 5% of adults worldwide. Fibromyalgia is believed to be a
central
nervous system condition, resulting from neurological changes in how
the brain ... and commercialization of
innovative medicines with a focus on central
nervous system and immunology
disorders. Employing around 12,000 people in over 40 ...
Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
... targets the heart, joints, skin,
lungs, blood vessels, liver, kidneys and
nervous system.
Lupus is characterized by periods of flares, or ... of innovative medicines
with a focus on the fields of central
nervous system and immunology
disorders. Employing approximately 12,000 people in ...